Liquid Robotics Announces Next Generation of the Wave Glider, Unmanned Surface Vehicle
Enhanced platform extends operations in high sea states and high latitudes
SUNNYVALE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Liquid Robotics, the leader in long duration, unmanned surface vehicles, today announced the next generation of the Wave Glider with advancements to the platform's operational range, and performance for missions in high sea states and high latitudes. Changes also include advancements for expanded sensor payloads and increased energy and storage capacity required for long duration maritime surveillance, environmental monitoring and observation missions.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4e644879-0454-41d2-999c-3c90e46cabfc
"From the very first Wave Glider we've had a passion and relentless commitment to make the world's best unmanned ocean robot," said Roger Hine, CTO and Co-founder, Liquid Robotics. "With our next generation Wave Glider, we've applied learning from approximately 100 years of cumulative water time to enhance an already well-proven design. The result is our Wave Gliders are better prepared than ever before to tackle the dull and dangerous missions."
Customers conducting exploration and surveillance missions in challenging environments are deploying Wave Gliders to collect and communicate data from locations too remote or too dangerous for manned systems. Operating through a wide range of conditions and oceans around the world, including the Artic (latitude of 78.76N) and Southern Ocean (latitude of 64.8S), this new version builds on the current platform capabilities with the following innovations:
Performance in high sea states (sea state 6 and greater)
- Advanced navigation in high latitudes (ex: Artic and Antarctica)
- Supports 30% heavier payloads to enable new sensors and missions
- 15% greater power collection and 40% more battery storage extends operational range and support for larger sensor payloads
- Anti-biofouling copper coating improves system performance and simplifies maintenance
"As we prepared for our deployment in the Southern Ocean, one of the most inhospitable ocean regions on the planet, it was clear that a successful mission required the next generation Wave Glider enhancements to provide reliable operations across the full spectrum of high seas we would encounter," said Dr. Eric Terrill of the Scripps Institution of Oceanography. "We've worked with early versions of this platform off the coast of Iceland for an extreme seas study, and the Wave Glider performed admirably even in seas in excess of 10 meters (sea state 9), so we knew for peace of mind, our Southern Ocean project would require a similar configuration."
For existing customers, an upgrade kit has been developed to expand the capabilities of their existing Wave Glider to match those of the new platform. All sensor integration validated on the current platform is compatible with the new system without new certification. General availability for this new version is October 2017.
About Liquid Robotics, A Boeing Company:
Liquid Robotics designs and manufactures the Wave Glider, the first wave and solar powered unmanned ocean robot. With our partners, we address many of the planet's greatest challenges, by transforming how to assess, monitor, and protect the ocean. We solve critical problems for defense, commercial, and science customers. Visit www.liquid-robotics.com to learn more.
Liquid Robotics and Wave Glider are registered trademarks of Liquid Robotics, Inc., a wholly owned subsidiary of The Boeing Company. For media questions, please contact: Joanne Masters at firstname.lastname@example.org.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Liquid Robotics via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00 | Pressmeddelande
Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressmeddelande
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressmeddelande
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum